Ulcerative colitis (UC) specifically affects the colon and rectum through multifactorial
mechanisms associated with genetic alterations, environmental factors, microbiota, and …

Background Inflammatory bowel diseases [IBD]―ulcerative colitis and Crohn's disease―are
commonly treated with biologic drugs. However, only approximately two-thirds of patients …

Crohn's disease and ulcerative colitis are chronic inflammatory disorders resulting from
immune dysregulation. Patients who fail conventional medical therapy require biological …

The advent of anti-TNF agents as the first approved targeted therapy in the treatment of
inflammatory bowel disease (IBD) patients has made a major impact on our existing …

Background & Aims Administration of infliximab to patients with acute severe ulcerative
colitis (ASUC)(rescue therapy) can reduce the rate of early colectomy (within 12 months), but …

Objective Anti-tumour necrosis factor (TNF) antibodies are successfully used for treatment of
Crohn's disease. Nevertheless, approximately 40% of patients display failure to anti-TNF …

Primary nonresponse and primary nonremission are important limitations of tumor necrosis
factor (TNF) antagonists, occurring in 10% to 40% and 50% to 80% of patients with …

Objective The aim of this study was to assess the correlation between serum and intestinal
anti-tumour necrosis factor (TNF) levels, and their relationship to endoscopic disease activity …

Infliximab was the first monoclonal antibody to be approved for the treatment of pediatric and
adult patients with moderately to severely active Crohn's disease (CD) and ulcerative colitis …

Abstract Background and Aims: Anti-tumour necrosis factor [TNF] therapy is used in patients
with ulcerative colitis [UC], but not all patients respond to treatment. Antimicrobial peptides …